Global Cell and Gene Therapy (CGT) Growth Opportunities

Global Cell and Gene Therapy (CGT) Growth Opportunities

The Shift to Prevalent Diseases and Allogeneic Cell Therapies Creates New Growth Opportunities in the CGT Value Chain

RELEASE DATE
16-Aug-2022
REGION
North America
Research Code: PD67-01-00-00-00
SKU: HC03570-NA-MT_26807
AvailableYesPDF Download

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03570-NA-MT_26807

$4,950.00

$4,207.50save 15 %

DownloadLink
ENQUIRE NOW

Description

This Frost & Sullivan study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-modified cell therapy, and gene therapy), and it also focuses on subsegments (allogeneic versus autologous; ex vivo versus in vivo). Market forecasts run from 2022 through 2027, and they capture key market developments, such as capacity expansion, mergers and acquisitions, and extension of services offerings set to impact overall CGT market growth. As CGT moves from ultra-rare indications to more common indications, the rapid expansion of manufacturing capabilities to support the commercial requirements of these diseases will become a necessity. The migration from paper-based data to the digital format will connect individual patient supply chain data with individual patient clinical data and incorporate it into the overall analysis. Time and speed will become crucial factors to stay ahead of the competition and reap the resulting benefits. The success of CGT in prevalent diseases, such as diabetes and stroke, will be the game changer during the forecast period and lead to new market access models.

The research service also covers the following topics:
• Market and Pipeline Snapshot
• Key Trends and Value Chain Analysis
• CGT Investment and M&A Snapshot
• CGT Reimbursement Snapshot
• CGT Regulatory Snapshot
• Drivers and Restraints
• Recent Acquisitions and Capacity Expansion by Major Bio-CDMOs

Author: Surbhi Gupta

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Global CGT Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Key Highlights

Scope of Analysis

Segmentation

Definitions

Growth Metrics

Growth Drivers

Growth Restraints

Forecast Assumptions

Revenue Forecast

Revenue Forecast by Product

Revenue Forecast Analysis

Revenue Forecast by Region

Revenue Forecast Analysis by Region

Competitive Environment

Revenue Share

Revenue Share Analysis

Key Approved CGTs Until Q1 2022

Key Approved CGTs Until Q1 2022 (continued)

Upcoming Regulatory Approvals in the US and the EU

Pipeline Snapshot

Gene Therapy and Genetically Modified Cell Therapies: Pipeline Snapshot

Cell Therapies: Pipeline Snapshot

CGT for Cancer: A Snapshot

CGT Value Chain

CGT Stakeholder Ecosystem

Traditional Drugs versus CGT Business Models

Evolving CGT Business Model: Orchestrated Collaborations between Stakeholders across the Value Chain

Key CGT Stakeholders’ Portfolio Strategies

CGT Value Chain: Evolving Role of Stakeholders in Digitalization

Winning Strategies for CGT Companies

Key Trends Driving Investment, Expansion, Partnerships, and M&As

Key Trends Driving Investment, Expansion, Partnerships, and M&As (continued)

Trends in CGT Investment, 2021

Notable Start-up Financing, 2021

Notable M&As, 2021–Q1 2022

Current Reimbursement Approach for CGTs: US and EU5

Current Reimbursement Approach for CGTs: APAC

Examples of Innovative CGT Reimbursement Models

Current Formal Regulatory Meetings with US and EU Regulatory Agencies

Approval Exemptions for CGT

Early Access Programs for CGT: Facilitated Approval

Early Access Programs for CGT: Priority Review

Early Access Programs for CGT: Priority Designation

Early Access Programs for CGT: Orphan Drug Designation

Regulatory Risk Assessment in Early Development

China’s Regulatory Environment has Drastically Evolved and Became Supportive for CGT Development, Leading to the Expansion of the Domestic CGT Industry

Growth Metrics, Cell Therapy

Revenue Forecast: Cell Therapy

Revenue Forecast by Source

Revenue Forecast Analysis

Growth Metrics, Gene Therapy

Revenue Forecast: Gene Therapy

Revenue Forecast by Technology

Revenue Forecast Analysis

Growth Metrics, Gene-modified Cell Therapy

Revenue Forecast: Gene-modified Cell Therapy

Revenue Forecast by Source

Revenue Forecast Analysis

Growth Opportunity 1: Internal Capabilities for GMP-grade Plasmid Manufacturing

Growth Opportunity 1: Internal Capabilities for GMP-grade Plasmid Manufacturing (continued)

Growth Opportunity 2: Early Adoption of RWE to Facilitate CGT Approval and Access

Growth Opportunity 2: Early Adoption of RWE to Facilitate CGT Approval and Access (continued)

Growth Opportunity 3: Application of CRISPR/Cas9 to Develop Allogeneic Cell-based Immuno-oncology Therapies

Growth Opportunity 3: Application of CRISPR/Cas9 to Develop Allogeneic Cell-based Immuno-oncology Therapies (continued)

Growth Opportunity 4: Scalable Bioreactors and Cryopreservation Solutions

Growth Opportunity 4: Scalable Bioreactors and Cryopreservation Solutions (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

This Frost & Sullivan study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-modified cell therapy, and gene therapy), and it also focuses on subsegments (allogeneic versus autologous; ex vivo versus in vivo). Market forecasts run from 2022 through 2027, and they capture key market developments, such as capacity expansion, mergers and acquisitions, and extension of services offerings set to impact overall CGT market growth. As CGT moves from ultra-rare indications to more common indications, the rapid expansion of manufacturing capabilities to support the commercial requirements of these diseases will become a necessity. The migration from paper-based data to the digital format will connect individual patient supply chain data with individual patient clinical data and incorporate it into the overall analysis. Time and speed will become crucial factors to stay ahead of the competition and reap the resulting benefits. The success of CGT in prevalent diseases, such as diabetes and stroke, will be the game changer during the forecast period and lead to new market access models. The research service also covers the following topics: • Market and Pipeline Snapshot • Key Trends and Value Chain Analysis • CGT Investment and M&A Snapshot • CGT Reimbursement Snapshot • CGT Regulatory Snapshot • Drivers and Restraints • Recent Acquisitions and Capacity Expansion by Major Bio-CDMOs Author: Surbhi Gupta
More Information
Author Surbhi Gupta
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 CGT Market
Keyword 2 Cell and Gene Therapy
Podcast No
WIP Number PD67-01-00-00-00